BIKSWITCH Study: Effectiveness and Safety of Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Therapies Not Based on Integrase Inhibitors in Virologically Suppressed HIV‐Infected Patients
The results of this study suggest that patients can switch to B/F/TAF from non-INSTI-based therapies without compromising the effectiveness or safety of ART.
Authors
- Francisco Jover (ORCID: https://orcid.org/0000-0002-1939-4295)
- Elisabet Delgado-Sánchez (ORCID: https://orcid.org/0009-0001-5408-281X)
- Jorge Peris-García (ORCID: https://orcid.org/0000-0002-0238-9350)
- María Ángeles Bernabeu (ORCID: https://orcid.org/0000-0003-0984-1888)
- Fernando Pérez-Calvo (ORCID: https://orcid.org/0009-0005-1637-8387)
Institutions
- Universitat de Miguel Hernández d'Elx (ES)
- Hospital Universitari Sant Joan D'Alacant (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
Publication Details
- Journal
- AIDS Research and Treatment
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1155/arat/8818830
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Gilead Sciences